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ABSTRACT 
This review will concentrate on the clinical pharmacology, in particular pharmacodynamic 
data, related to atypical antipsychotics, clozapine, risperidone, paliperidone, olanzapine, que-
tiapine, amisulpride, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone and caripra-
zine. A summary of their acute pharmacokinetics properties are also reported. 
Four new second-generation antipsychotics are available: iloperidone, asenapine, lurasidone 
and in the next future cariprazine. Similar to ziprasidone and aripiprazole, these new agents 
are advisable for the lower propensity to give weight gain and metabolic abnormalities in 
comparison with older second-generation antipsychotics such as olanzapine or clozapine. Ac-
tually lurasidone seems to be best in terms of minimizing unwanted alterations in body weight 
and metabolic variables. 
Therapeutic drug monitoring is not strictly necessary for all of the new antipsychotic drugs 
because there are no unequivocal data supporting a relationship between plasma drug levels 
and clinical outcomes or side effects. The exception can be represented by clozapine for 
which plasma levels of 350-420 ng/ml are reported to be associated with an increased proba-
bility of a good clinical response. Also for olanzapine an established therapeutic range (20-
50 ng/ml) is proposed to yield an optimal response and minimize side effects. 
 
 
 
INTRODUCTION 
The primary distinction between classical 
and second-generation antipsychotics has 
been made on clinical basis. Actually con-
ventional or “typical” antipsychotics are 
characterized by undesirable side effects 
such as extrapyramidal symptoms (EPS), 
hyperprolactinaemia, tardive dyskinesia and 
possible neuroleptic malignant syndrome. 
These symptoms are specific to the group as 
a whole and generally associated with high 
doses but in some cases also at clinically ef-
fective dosages. The second-generation or 
“atypical” antipsychotic drugs can be differ-
entiated from traditional antipsychotics by 
their low or negligible levels of these un-
wanted side effects, by effectiveness and in 
general supposed increased safety. This latter 
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has been recently questioned for the inci-
dence of symptoms linked to metabolic syn-
drome. 
The multiple clinical and adverse effects 
of different antipsychotics depend on the 
combination of receptors occupancy, but the 
dopamine pathway is still considered the 
primary common target for all antipsychotic 
drugs. More specifically, no drug has yet 
been identified with antipsychotic action 
without a significant affinity for D2 recep-
tors. 
There are 5 types of dopamine receptors 
in human beings: types 1 and 5 are similar in 
structure and drug sensitivity, and these two 
receptors are referred to as the "D1like" 
group or class of receptors. Dopamine recep-
tor types 2, 3, and 4 are also similar in struc-
ture and are, therefore, grouped together as 
the "D2like" group. Dopamine receptors 2, 3 
and 4, however, have significantly different 
sensitivities to antipsychotic drugs. 
Although the D1like receptors are men-
tioned as a primary target for antipsychotic 
drugs, several findings indicate that they are 
not clinically relevant. 
Of the 3 D2like receptors, only the D2 
receptor itself is blocked by antipsychotic 
drugs in direct relation to their clinical anti-
psychotic potencies. In particular the clinical 
efficacy of antipsychotics is associated with 
a blockade of 60 % to 80 % of D2 receptors 
in the brain as measured by positron emis-
sion tomography (PET) or single photon 
emission tomography (SPET). 
D2 receptor blockade in the brain is a 
general pharmacodynamic property of all 
antipsychotics, and without it a drug will 
not show any antipsychotic properties. 
With conventional antipsychotics the 
level of D2 receptor blockade is directly 
related to the antipsychotic effect but with 
atypical agents the situation is more com-
plicated (Seeman, 2002; Meltzer, 2002). 
Three theories for atypical antipsychotic 
action are reported. The "fast-off-D2" theory 
proposes that typical antipsychotics bind 
more tightly than dopamine to the dopamine 
D2 receptor in its functional high-affinity 
state, with dissociation constants lower than 
that for dopamine. On the contrary, the atyp-
icals bind more loosely than dopamine to the 
dopamine D2 receptor, with dissociation con-
stants higher than that for dopamine. A typi-
cal example is represented by clozapine and 
quetiapine (Seeman, 2002; Meltzer, 2002). 
Rapid dissociation from D2 receptors is 
one explanation for the improved EPS pro-
file of atypical antipsychotics, and one that is 
also consistent with the theory of a lower 
affinity for D2 receptors for these drugs 
(Miyamoto et al., 2005; Horacek et al., 
2006). 
The dopamine-serotonin antagonism the-
ory generally predicts a separation between 
typicals and atypicals, except that out of 20 
antipsychotics there are apparent exceptions 
to this theory: amisulpride and remoxipride 
are an important exception. 
Blockade of 5HT2A and D2 receptors was, 
in 1989, first labelled a pharmacodynamic 
mechanism that differentiated conventional 
from atypical antipsychotics. Meltzer (2002) 
defined atypical antipsychotics as drugs 
showing a higher affinity for 5HT2A recep-
tors than for D2 receptors and a lower affini-
ty for D2 receptors than was seen with con-
ventional antipsychotics. For the nigrostriatal 
dopaminergic pathway, a model was sug-
gested in which blockade of 5HT2A receptors 
should lead to increased output of dopamin-
ergic neurons into the striatum leading to 
displace the antipsychotic drug from its bind-
ing to D2 receptors. This could decrease the 
risk of EPS development (Horacek et al., 
2006) (Figure 1). 
There is the theory which predicts that 
new antipsychotics stimulate S-HT2A recep-
tors by inverse agonism. Although it has 
long been known that the stimulation of 
5HT1A receptors in animals can alleviate cat-
alepsy caused by D2 blockade, there do not 
appear to be any antipsychotics that have this 
5HT1A stimulating action combined with D2 
blocking action. It has been proposed that the 
stimulation of 5HT2A receptors by an inverse 
action is an important contribution to atypi-
cal antipsychotic action. However, although 
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some authors proposed that M100,907 has 
the desired stimulating action, this com-
pound has shown no antipsychotic activity in 
humans. 
 
 
Figure 1: Atypical antipsychotics: proposed me-
chanisms of action (modified by Seeman, 2002) 
 
On the other hand the original classi-
fication of antipsychotics according to their 
chemical structure (i.e. phenothiazines, thio-
xanthenes, butyrophenones and diphenyl-
piperidines) and prevailing sedative or anti-
psychotic (incisiveness) potential is still rele-
vant for the conventional antipsychotic 
agents. The classification of atypical anti-
psychotics is linked essentially to their 
pharmacodynamic properties, which reflect 
their affinities for specific receptors. Atypi-
cal antipsychotics with a high selectivity for 
serotonin 5-HT2A receptors and dopamine D2 
receptors (and also α1-adrenoceptors) are 
called serotonin-dopamine antagonists 
(SDA) (risperidone, its metabolite paliperi-
done, ziprasidone, iloperidone, lurasidone). 
Drugs showing an affinity for 5-HT2A, D2 
and receptors of other systems (cholinergic, 
histaminergic, 5-HT1A, 5-HT1C and others) 
are designated as multi-acting receptor-
targeted antipsychotics (MARTA) (clozap-
ine, olanzapine, quetiapine, asenapine). 
Drugs that preferentially block D2 and D3 
subtypes of the D2-like receptors are classi-
fied as combined D2/D3 receptor antagonists 
(amisulpride). A final class of atypical anti-
psychotics are the partial dopamine receptor 
agonists (aripiprazole and cariprazine) 
(Horacek et al., 2006) (Figure 2, Table 1). 
Neuroplasticity refers to the ability of the 
nervous system to adapt to environmental 
changes and includes both synaptic plasticity 
consisting of remodelling of the synapses or 
development of new neuronal connections 
and neurogenesis with the development of 
new neurons. Atypical antipsychotics are 
reported to induce restructuring of neuronal 
networks by inducing neuroplastic changes. 
This effect contributes to a more substantial 
description of the interaction between anti-
psychotics and the neurodevelopmentally 
altered function and structure of the brain in 
schizophrenic patients. Moreover it can ex-
plain the longterm antipsychotic effect, sug-
gesting a remodelling of neuronal structures 
(Miyamoto et al., 2005). 
On the other hand there are evidences to 
indicate dysfunctions in the connectivity of 
glutamatergic neurons in schizophrenia. For 
example, reductions in the density of pre-
frontal cortex pyramidal cell dendrites, the 
number of glutamatergic synaptosomes and 
the expression of messenger RNA (mRNA) 
for the synaptic density marker synaptophy-
sin are found post mortem in patients who 
had schizophrenia (Horacek et al., 2006). 
The theory of glutamatergic dysfunction in 
schizophrenia is also supported by the fact 
that phencyclidine and other antagonists of 
glutamatergic NMDA receptors may, from 
the phenomenological point of view, model 
the schizophrenic symptoms in healthy per-
sons better than serotonergic psychotomi-
metic drugs (e.g. LSD). Moreover these sub-
stances can aggravate or exacerbate psycho-
sis in patients with schizophrenia. All the
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Figure 2: Simplified receptor binding affinity profiles for atypical antipsychotics 
Blue, potentially therapeutics, red, potentially side effects, receptor binding affinities. The two recep-
tors with asterisks 5HT2C and D2 should be both therapeutic and side effects inducing. The yellow line 
indicates the D2 affinity level for each drug (modified by Cutler et al., 2008) 
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Table 1: Proposed mechanisms of action of atypical antipsychotics (modified by Horacek et al., 2006) 
Dopaminergic modulation 
- Blockade D2 - blockade of 65-75 % leads to effectiveness with preserved safety (EPS and hy-
perprolactinaemia) 
- Blockade D1 - is localized in PFC: therapeutic effect on negative and cognitive symptoms. D1 
modulate activity of D2 (potentiation of efficiency). D1 antagonism alone no antipsychotic effect 
- Blockade D4 - decreases catalepsy and induces dopamine release in the basal ganglia and PFC. 
D4 antagonism alone no antipsychotic effect 
- Blockade of D2/D3 - preferential antagonism of inhibitory D2 autoreceptors; increased striatal 
(lower risk of EPS) and neocortical dopamine release (cognitive and negative symptoms) 
- Blockade of D3 receptors in temporal cortex, leads to stereoselectivity and efficacy on positive 
symptoms without induction of EPS 
- Rapid dissociation from D2 (“fast OFF”) - shorter duration of drug binding to D2 is sufficient for an 
antipsychotic action but insufficient to induce EPS and hyperprolactinaemia (particularly quetia-
pine and clozapine)  
- Partial D2 agonism - aripiprazole, 30-40 % of intrinsic D2 receptor agonism in connection with 
high D2 blockade exerts an antipsychotic effect with a low risk of EPS and hyperprolactinaemia 
Serotonergic modulation 
- Blockade of 5-HT2A - 5-HT2A receptors integrate cortical and subcortical inputs. Antagonism of 5-
HT2A blocks the effect of NMDA antagonists and induces striatal and neocortical dopamine re-
lease 
- 5-HT1A  agonism - induces dopamine release into the striatum and neocortex (analogous to 5-
HT2A blockade) and also into limbic structures 
- Blockade of 5-HT2C - induces neocortical dopamine release 
- Modulation of 5-HT2A, 5-HT1A and 5-HT2C alone no antipsychotic effect 
Induction of neuroplasticity 
- Phosphorylation of receptors, potentiation of glutamate/glycine and induction of neuronal growth 
factors (NGF and BDNF): reinforcement of NMDA receptor activity and development of new syn-
apses or their remodelling 
BDNF = brain-derived neurotrophic factor; EPS = extrapyramidal side effects; NGF = nerve growth 
factor; PFC = prefrontal cortex 
 
 
 
antipsychotic drugs affect the glutamatergic 
system directly as partial agonists at the 
NMDA receptor-associated glycine recogni-
tion site and indirectly by the blockade of 
glycine and glutamate transporters at the 
synaptic level. By this mechanism, deficient 
glutamatergic signalling would be potentiat-
ed (Table 2). 
This explanation is supported by the 
finding that the glutamate coagonist glycine 
and its derivatives (D-serine, D-cycloserine), 
as well as inhibitors of glycine reuptake, 
might potentiate the clinical effect of con-
ventional antipsychotics. 
Actually, bitopertin is an oral, small mol-
ecule first-in-class glycine reuptake inhibitor 
(GRI). Bitopertin enhances N-methyl-D-
aspartate (NMDA) receptor activity, thereby 
targeting at least theoretically an important 
pathway in the treatment of psychiatric dis-
orders, especially schizophrenia (Green et 
al., 2011). However, clinical trials on this 
type of molecules do not seem to always an-
swer to desired expectations. 
The aim of this review is to update the 
data relating to the pharmacodynamics and 
pharmacokinetics of atypical antipsychotics. 
It will consider the following currently avail-
able second-generation antipsychotics, 
clozapine, risperidone, paliperidone, olan-
zapine, quetiapine, aripiprazole, ziprasidone, 
amisulpride, asenapine, iloperidone, lura-
sidone and cariprazine. 
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Table 2: Potential clinical efficacy and benefits related to the mechanisms of action of antipsychotics 
(modified by Miyamoto et al., 2005) 
Mechanisms of action Clinical efficacy Possible effects 
D2 antagonism ↓ positive symptoms EPS 
↓negative symptoms 
↑ cognitive symptoms 
D2 partial agonism ↓ positive symptoms   
↓ negative symptoms 
↓ cognitive symptoms 
 
little or no EPS 
behavioral activation 
↑DA and NE release in the 
PFC 
↓ negative symptoms 
↓ cognitive symptoms 
↓ depressive symptoms 
behavioral activation 
ACh release in the PFC ↓ cognitive symptoms  
5-HT2A antagonism  ↓ negative symptoms  ↓ EPS 
5-HT1A partial agonism 
 
↓ negative symptoms 
↓ cognitive symptoms 
↓ anxiety symptoms 
↓ depressive symptoms 
 
Muscarinic  antagonism ↓ EPS ↓ anticholinergic symptoms 
e.g. dry mouth, constipation, 
tachycardia 
Muscarinic agonism  
 
 
↓ psychotic symptoms 
↓ cognitive symptoms 
 
Glutamate modulation 
 
↓ positive symptoms 
↓ negative symptoms 
↓ cognitive symptoms 
↓ illness progression 
 
NE, norepinephrine; ACh, acetylcholine; PFC, prefrontal cortex; EPS, extrapyramidal symptoms 
 
 
Clozapine 
Clozapine (CLZ), still actually the main 
stone of atypical antipsychotics, belongs to 
the chemical class of the dibenzodiazepines. 
It has many unique clinical advantages over 
typical neuroleptic agents, including its effi-
cacy in treatment-refractory schizophrenia, a 
low propensity to induce extrapyramidal 
symptoms (EPS), particularly tardive dyski-
nesia, and it does not increase serum prolac-
tine levels. In addition to being efficacious 
against positive symptoms, CLZ may also be 
beneficial in treating negative symptoms. It 
has been demonstrated to prevent suicidal 
tendencies and some types of cognitive defi-
cits associated with schizophrenia (Meltzer 
et al., 1989). 
CLZ has much greater antagonistic activ-
ity on cortical and limbic dopamine D4 than 
D2 receptors. It also antagonizes 5HT2 sero-
toninergic receptor subtypes (5HT2A 5HT2C) 
and adrenergic (α1), histamine (H1) and mus-
carinic receptors (M1) (Meltzer, 1992). 
In an extended series of patients, PET 
studies (Nordstrom et al., 1995) confirm that 
CLZ is atypical with regard to degree of D2 
receptor occupancy, a finding that may ex-
plain the lack of extrapyramidal side effects. 
The combination of relatively high D1, low 
D2, and very high 5-HT2 receptor occupancy 
rates is unique to CLZ. 
Furthermore, binding studies have shown 
that the concentrations capable of blocking 
75 % of D4 dopamine receptors match the 
therapeutic concentrations (Seeman and Van 
Tool, 1995). On the other hand, another 
study suggested that inherited variants of D4 
may explain some of the interindividual var-
iation seen in patients’ response to CLZ 
(Zhao et al., 2005). 
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From the pharmacokinetic point of view, 
CLZ is rapidly absorbed after oral admin-
istration. Food does not seem to affect the 
amount of drug absorbed. Only 27-50 % of 
the dose reaches the systemic circulation un-
changed due to extensive first-pass metabo-
lism. 
CLZ shows a wide interindividual range 
with mean half-lives ranging from 9.1 to 
17.4 h. The time to peak plasma concentra-
tion is between 1.1 and 3.6 h, plasma clear-
ance between 8.7 and 53.3 L/h and distribu-
tion volume between 1.6 and 7.3 L/kg (Jann 
et al., 1993). Steady-state plasma concentra-
tions are reached after 7-10 days of dosing. 
CLZ is 95 % bound to plasma proteins, pri-
marily alpha1-glycoprotein (Choc et al., 
1990). 
Several studies have assessed the rela-
tionship between plasma CLZ levels and 
clinical responses (Perry et al., 1991; Potkin 
et al., 1994; Kronig et al., 1995; Mauri et al., 
2004a). It has been suggested that monitor-
ing plasma CLZ concentrations might be 
useful in clinical management, but the effec-
tive plasma CLZ window remains debated 
(Freeman and Oyewumi, 1997; Khan and 
Preskorn, 2005). Most researchers find that a 
threshold plasma level of 350-420 ng/ml of 
CLZ is associated with an increased proba-
bility of a good clinical response to the drug. 
Moreover, much of the reviewed data indi-
cate that increasing the oral CLZ dose in non 
responder patients to achieve a plasma level 
of at least 350-420 ng/ml can increase the 
number of CLZ responders (Potkin et al., 
1994; Fabrazzo et al., 2002; Mauri et al., 
2007a). Plasma CLZ concentrations (and the 
probability of reaching a given threshold) 
may be influenced by many factors such as 
age, gender and smoking (Schulte, 2003). 
Therapeutic drug plasma level monitor-
ing (TDM) is useful in the case of suspected 
poor compliance and for patients with altered 
pharmacokinetics, such as those character-
ized by ultrarapid CYP1A2 activity. This 
could lead to low plasma CLZ levels and a 
non-response that requires the use of very 
high CLZ doses or the co-administration of a 
strong CYP1A2 inhibitor (e.g. fluvoxamine) 
(Eap et al., 2004). Moreover, the high inter-
individual and low intraindividual variability 
of plasma CLZ levels confirm the usefulness 
of monitoring them. 
 
Risperidone 
Risperidone (RSP) is an approved anti-
psychotic agent for the treatment of schizo-
phrenia and the acute manic phase of bipolar 
disorder. It is effective in both the short- and 
longterm treatment of schizophrenia, has a 
rapid onset of action, and is efficacious in 
treating both positive and negative symp-
toms (Rabinowitz and Davidson, 2001). It 
has a lower acute incidence of side effects 
than haloperidol at least at therapeutical dos-
ages of 4-6 mg/day (Peuskens, 1995; Ems-
ley, 1999). 
RSP is a benzisoxazole derivative, and 
has a strong binding affinity for serotonin (5-
HT2A and 5-HT7) and dopamine D2 receptors 
(its affinity for D3 and D4 receptors is three 
times lower), with a 5HT2A/D2 affinity ratio 
of about 20. It also has a high affinity for ad-
renergic (1 and 2) receptors, and a low af-
finity for histamine (H1) receptors (Ereshef-
sky and Lacombe, 1993; Leysen et al., 
1998). 
From a pharmacokinetic point of view 
RSP is rapidly absorbed after oral admin-
istration, with peak plasma concentrations 
being reached in about one hour; its rather 
good oral bioavailability is about 70-85 %. It 
mainly undergoes 9-hydroxylation in the liv-
er that yields the active 9-hydroxy-risperi-
done metabolite (9-OH-RSP), a step that is 
mainly catalysed by CYP2D6 and, to a lesser 
extent, CYP3A4; alicyclic dehydroxylation 
and oxidative N-dealkylation are minor met-
abolic pathways (Mannens et al., 1993). As 
the pharmacological properties of 9-OH-RSP 
are similar to those of RSP, both are regard-
ed as being able to contribute to the drug’s 
overall antipsychotic effects in the treatment 
of schizophrenia, and thus represent “the ac-
tive moiety”. 
Genetic influences, such as CYP2D6 sta-
tus, play an important role in determining the 
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variability of its pharmacokinetic parameters. 
The mean half-life of RSP is three hours in 
extensive metabolizers (the majority of pop-
ulation), and 22 hours in poor metabolisers; 
the mean half-life of the “active moiety” 
(RSP and its main metabolite) is almost con-
stant at about 22 hours in both groups. 
Steady-state levels are reached within five 
days of treatment. RSP and its main metabo-
lite are 89 % and 77 % bound to plasma pro-
teins (Leysen et al., 1998). The mean plasma 
clearance of RSP is 5.4 ± 1.4 ml/min/kg, and 
the distribution volume is 1.1 l/kg. Most of 
the 9-OH-RSP is removed by means of renal 
excretion; it undergoes little further hepatic 
metabolism. 
Aravagiri et al. (2003) showed a large in-
tra- and interindividual variation in the plas-
ma concentrations of both RSP and 9-OH-
RSP. The latter seems to be the major circu-
lating active moiety and its plasma concen-
trations are 22-fold higher than those of RSP. 
The authors described a weak relationship 
between the daily dose and plasma concen-
trations of RSP, but a close relationship with 
the concentrations of 9-OH-RSP and those of 
the total active moiety. The same authors 
showed that the administered dose and dura-
tion of treatment did not have any effect on 
the metabolism of RSP to 9-OH-RSP. The 
concentrations of RSP seemed to vary more 
widely than those of its metabolite, and the 
relationship of both 9-OH-RSP and the ac-
tive moiety to the administered dose was 
closer than that of RSP. The authors con-
cluded that measuring the plasma levels of 
the parent compound (RSP) alone may lead 
to erroneous interpretations in plasma level 
monitoring studies (Aravagiri et al., 1998, 
2003). 
Other authors have also reported that 
there is a linear but often weak relationship 
between the RSP dose and mean plasma 
RSP, 9-OH-RSP and active moiety levels 
(Ereshefsky and Lacombe, 1993; Grant et 
al., 1994; Spina et al., 2001; Riedel et al., 
2005) but Mauri et al. (2001) and Chen et al. 
(2004) found no significant relationship. 
It is available also a long-acting injecta-
ble RSP (RSP microsphere). RSP has been 
the first atypical antipsychotic agent to be 
available in a long-acting formulation: the 
intramuscular depot formulation called 
"long-acting injectable (LAI) RSP" is an 
aqueous suspension in a matrix of glycolic 
acid-lactate polymer. 
Gefvert et al. (2005) studied the relation-
ship between brain D2 receptor occupancy 
and LAI RSP in 13 patients with schizophre-
nia two weeks after the third and fifth injec-
tions. Injections of 25, 50 and 75 mg respec-
tively led to D2 receptor occupancy rates of 
25-48 %, 59-83 % and 62-72 %, and plasma 
active moiety levels of 4.4-8.8, 15.0-31.1 
and 22.5-26.3 ng/ml. The results indicate 
that brain D2 receptor occupancy at steady-
state after injections of LAI RSP is within 
the range observed in patients effectively 
treated with 2-6 mg of oral RSP. 
From a pharmacokinetic point of view 
the plasma concentrations of free RSP in-
crease gradually, peak after about five 
weeks, and are detectable for up to seven 
weeks after a single intramuscular injection. 
Administration intervals of approximately 
two weeks are commonly used (Kelleher et 
al., 2002). 
The single dose pharmacokinetic profiles 
of LAI and oral RSP were extrapolated to 
steady-state in a study by Mannaert et al. 
(2005). Plasma concentrations of the active 
moiety (unchanged RSP+9-OH-RSP) were 
measured by radioimmunoassay up to 72 h 
after a single oral dose of RSP 1 mg in 12 
healthy volunteers, and up to 84 days after a 
single intramuscular injection of LAI RSP 
50 mg in 26 schizophrenic patients. The 
most interesting results obtained at steady-
state were that LAI RSP a lower than pre-
dicted peak plasma level (46 vs 62 ng/ml) 
and a lower than predicted degree of fluctua-
tion between Cmax and Cmin (53 vs 145 %). 
The pharmacokinetic profile of LAI RSP 
administered every two weeks ensures the 
maintenance of steady-state. 
It has been demonstrated a bioequiva-
lence of the LAI and oral formulations, but 
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the mean peak steady-state peak concentra-
tions of the active moiety were 25-32 % 
lower with LAI than oral RSP, and their 
fluctuations were 32-42 % lower (Eerdekens 
et al., 2004; Nesvag et al., 2006). 
In some patients who had previously re-
ceived oral RSP, switching to the LAI for-
mulation led to an average increase in the 
C/D ratio of 33 % (range 12 %-68 %) (Cast-
berg and Spigset, 2005). 
The available data do not make it possi-
ble to establish the value of RSP therapeutic 
drug monitoring in absolute terms. The over-
all pharmacological effects of RSP depend 
on the sum of the plasma concentrations of it 
and its 9-OH-RSP metabolite (the “total ac-
tive moiety”), and so monitoring the plasma 
levels of the parent compound (RSP) alone 
can lead to erroneous interpretations (Arava-
giri et al., 2003). It seems that monitoring the 
plasma levels of the active moiety may be 
useful, but further investigations are required 
in order to clarify the discrepancies in the 
results obtained so far. 
It is important to understand whether 
there is a positive correlation between clini-
cal responses and plasma levels of active 
moiety: some authors have reported a nega-
tive correlation (Riedel et al., 2005) which 
conflicts with previously published data 
(Mauri et al., 2001; Odou et al., 2000). This 
discrepancy may be due to the large variabil-
ity in plasma drug levels and the lack of 
studies using fixed dosages. No therapeutic 
plasma level range for RSP has yet been 
clearly established: the plasma threshold for 
parkinsonian side effects has been found to 
be of 74 ng/ml (Peuskens et al., 1995; 
Marder and Meibach, 1994) but it is not 
clear what is the minimum effective plasma 
concentration of the active moiety. Some da-
ta suggest that the normal range is between 
15 and 60 ng/ml, but they need to be con-
firmed (Mauri et al., 2001; Odou et al., 2000; 
Darby et al., 1997). According to the AGNP 
consensus guidelines, RSP TDM is recom-
mended and the proposed plasma RSP con-
centrations are between 20 and 60 ng/ml. 
Moreover, RSP TDM should be particularly 
useful when medication is switched from the 
oral to the depot form, or vice versa (Bau-
mann et al., 2004). 
 
Paliperidone 
Paliperidone is a novel antipsychotic 
agent belonging to the benzisoxazole-
derivatives class. Paliperidone is the major 
active metabolite of risperidone (OH-RSP). 
Paliperidone is a centrally active dopa-
mine D2 antagonist with predominant sero-
tonergic 5-HT2A antagonistic activity. Pali-
peridone is also active as an antagonist at α1 
and α2 adrenergic receptors and H1 hista-
minergic receptors. Paliperidone has no af-
finity for cholinergic muscarinic or β1- and 
β2-adrenergic receptors. The pharmacologi-
cal activity of the (+)– and (-)- paliperidone 
enantiomers is qualitatively and quantitative-
ly similar. 
Paliperidone extended-release (ER) is 
approved in the United States, Europe, and 
globally for the treatment of schizophrenia in 
adults and in adolescents aged 12-17 years. It 
is also approved for the treatment of adults 
with schizoaffective disorder, both as a 
monotherapy and as adjunctive therapy to 
mood stabilizers and/or antidepressants. 
It is formulated using OROS® (osmotic 
controlled-release system, ALZA Corpora-
tion, CA, USA) technology, which reduces 
peak-to-trough variations in plasma concen-
trations and eliminates the need for initial 
dose titration (Conley et al., 2006). Paliperi-
done ER is also minimally metabolized in 
the liver and thus has a lower potential for 
clinically significant pharmacokinetic drug 
interactions with drugs that are metabolized 
by the cytochrome P450 (CYP450) enzyme 
system. Furthermore, no dose adjustment of 
paliperidone ER is needed in patients with 
mild-to-moderate hepatic impairment. 
In a 6-week dose-finding study of pali-
peridone ER in male patients with schizo-
phrenia using positron emission tomography, 
paliperidone ER at 6-9 mg/day resulted in an 
estimated dopamine D2 receptor occupancy 
of between 70 and 80 % in the striatum and 
in the temporal cortex (Citrome, 2012a). 
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Paliperidone palmitate is the long-acting 
injectable (LAI) formulation of the approved 
oral antipsychotic paliperidone ER for the 
treatment of schizophrenia. 
Paliperidone palmitate is an ester in an 
aqueous-based nano-suspension. It has very 
low water solubility. After injection, paliper-
idone palmitate slowly dissolves and is hy-
drolyzed to paliperidone by esterases in the 
muscle tissue. It is intended for once-
monthly intramuscular injection and it does 
not require any oral supplementation (Gilday 
and Nasrallah, 2012). 
 
Olanzapine 
Olanzapine (OLZ) is a thienobenzodiaz-
epine derivate structurally similar to clozap-
ine that is effective in treating schizophrenia 
and acute manic episodes, and in preventing 
the recurrence of bipolar disorders (McCor-
mack and Wiseman, 2004). It is as effective 
and safe as haloperidol in acute reducing the 
psychopathological symptoms of psychosis 
and has been shown to have some therapeu-
tic advantages over other classic antipsychot-
ics in terms of symptom reduction and its 
adverse event profile. It has a low propensity 
to cause extrapyramidal effects or sustained 
increases in prolactin levels (Lieberman et 
al., 2003). Nevertheless, treatment with OLZ 
(like CLZ) is associated with a higher risk of 
weight gain and, more extensively, metabol-
ic syndrome than other typical and atypical 
antipsychotics (Lambert et al., 2005; Duggan 
et al., 2005). 
OLZ shares higher affinity to 5-HT2A re-
ceptors than D2 receptors (high 5-HT2A/D2 
ratio). In comparison to the other atypicals, 
olanzapine presents high affinity for seroto-
ninergic 5-HT2A, 5-HT2C, 5-HT3, and 5-HT6 
receptors, medium affinity for dopaminergic 
D1, D2, D3, D4, D5, and muscarinic M1–M5 
receptors, 18 low affinity for adrenergic α1 
and α2 receptors, and the highest affinity for 
histamine H1 receptors (olanzapine is the 
most potent histamine H1 antagonist known) 
(Bymaster et al., 1999). 
OLZ selectively reduces the activity of 
dopaminergic mesolimbic (A10) neurons but 
not dopaminergic striatal (A9) neuron fire 
and, in animal studies, counteracts condi-
tioned avoidance behavior (test of antipsy-
chotic efficacy) at a dose that is not suffi-
cient to induce catalepsy (test of motor side 
effect) (Chiodo and Bunney, 1983; Stockton 
and Rasmussen, 1996; Frampton, 2010). 
More recently, preclinical studies have 
shown that OLZ efficacy on psychotic and 
cognitive symptoms of schizophrenia may be 
represented by its facilitating effect on N-
methyl-D-aspartic acid, which can favor 
brain derived neurotrophic factor (BDNF) 
expression (Horacek et al., 2006). According 
to another study, treatment with OLZ mark-
edly restored the reduction of both BDNF 
and tyrosine kinase (TrkB) receptors in hip-
pocampus, associated with previous treat-
ment with haloperidol (Parikh et al., 2004). 
Other studies mentioned that OLZ efficacy 
on negative and depressive symptoms of 
schizophrenia might be related to inhibition 
of norepinephrine transporter and modula-
tion of cytokine plasma level, as interleukin-
2 declined after 8-week olanzapine treatment 
(Hikaru et al., 2007; Schatzberg and Neme-
roff, 2013). 
Approximately 85 % of an oral OLZ 
dose is absorbed but, as about 40 % is inacti-
vated by first-pass hepatic metabolism, its 
oral bioavailability is about 60 %. OLZ has a 
mean half-life in healthy individuals of 
33 hours (range 21-54 hours). Peak plasma 
concentrations are reached within six hours. 
The drug is approximately 93 % bound to 
plasma proteins, mainly albumin (90 %) and 
alpha 1-acid glycoprotein (77 %). Its distri-
bution volume is 16.4 ± 5.1 L (SD). Mean 
apparent plasma clearance is 26 L/h (range 
12-47 L/h). Smokers and men show greater 
OLZ clearance than women and non-smok-
ers (Callaghan et al., 1999). After the admin-
istration of [14C]-OLZ in a single load phar-
macokinetic study, approximately 87 % of 
the radioactivity was excreted, with 30 % 
appearing in the feces and 57 % in the urine 
(Kassahun et al., 1997). Approximately half 
of the radiocarbon was excreted within three 
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days, and >70 % of the dose was recovered 
within seven days. 
OLZ is metabolized to its 10-N- and 4'-
N-glucuronides, 4'-N-desmethylolanzapine 
(by CYP1A2), and olanzapine-N-oxide (by 
flavin mono-oxygenase 3). Metabolism to 2-
hydroxymethylolanzapine via CYP2D6 is a 
minor pathway. The 10-N-glucuronide is the 
most abundant metabolite (Callaghan et al., 
1999). 
OLZ does not inhibit CYP isozymes. No 
clinically significant metabolic interactions 
have been found between OLZ and diaze-
pam, alcohol (ethanol), imipramine, racemic 
mixture - R and –S warfarin, aminophylline, 
biperiden, lithium or fluoxetine. Fluvoxam-
ine, an inhibitor of CYP1A2, increases the 
plasma concentrations of OLZ, whereas the 
inducers of CYP1A2 (including tobacco 
smoking) and UDP-glucuronyltransferase 
and CYP3A4 (such as carbamazepine) de-
crease them (Kassahun et al., 1997; Calla-
ghan et al., 1999). 
A number of studies have investigated 
the relationship between the daily OLZ dose 
and plasma OLZ concentrations showing 
that the latter increase linearly with the daily 
oral dose (0.12<r<0.68) (Kelly et al., 1999; 
Gex-Fabry et al., 2003; Mauri et al., 2005). 
Moreover, some authors have demonstrated 
a linear relationship between the prescribed 
daily dose and the plasma concentration of 
the major N-desmethylolanzapine metabolite 
(Olesen and Linnet, 1999). 
These studies showed that mean plasma 
OLZ concentrations vary widely, depending 
on factors such as the prescribed daily dose 
and the duration of treatment. Given their 
lower OLZ clearance, women have signifi-
cantly higher mean plasma OLZ levels, 
which become evident after the fifth week of 
treatment (Kelly et al., 1999; Gex-Fabry et 
al., 2003). At commonly used daily OLZ 
doses (5-30 mg/day), mean plasma concen-
trations can range from 10 to 54 ng/ml. Con-
siderable inter-patient variability has some-
times been observed, possibly due to unre-
ported co-medications, non-compliance, and 
intrinsic interindividual variability in drug 
metabolism and/or clearance (Gex-Fabry et 
al., 2003; Fellows et al., 2003). 
Only short-term studies of the relation-
ships between clinical responses and plasma 
OLZ levels have been carried out, none of 
which had a treatment period of more than 
six weeks. The reviewed studies strongly in-
dicate a relationship between clinical out-
comes and plasma OLZ concentrations (Per-
ry et al., 1997; Lane et al., 2002; Mauri et al., 
2005). Furthermore, given the large inter-
patient variability in plasma OLZ levels at 
the same doses, the monitoring of blood 
OLZ concentrations can be considered very 
useful in assessing therapeutic efficacy and 
controlling adverse events. A therapeutic 
range of between 20 ng/ml and 50 ng/ml has 
been found (Lane et al., 2002; Fellows et al., 
2003; Mauri et al., 2005). 
PET studies by Kapur et al. (1998) ana-
lyzed the differences in D2 receptor occu-
pancy on the basis of OLZ dose/plasma OLZ 
levels, and found that the relationship be-
tween plasma OLZ levels and D2 occupancy 
was described by a saturating rectangular 
hyperbola. OLZ is a potent 5-HT2 blocker 
and shows greater 5-HT2 than D2 occupancy 
at all doses. At a plasma concentration of 
10.3 ng/ml, OLZ occupied 50 % of the avail-
able D2 receptors. Within the usual clinical 
range of 10-20 mg/day, D2 occupancy varies 
from 71 % to 80 % (Kapur et al., 1998). Re-
cently, Attarbaschi et al. (2007) have ex-
plored the relationship between striatal D2 
receptor occupancy and EPS in 17 bipolar 
patients receiving OLZ 5-45 mg/day for at 
least 14 days, and found a significant corre-
lation between plasma levels and occupancy 
(R2= 0.55, P=0.001). The bipolar patients 
did not show any EPS at D2 occupancy lev-
els of 28-80 %.  
According to the AGNP-TDM consensus 
group, OLZ TDM is strongly recommended 
as an established therapeutic range (20-
50 ng/ml) is proposed to yield an optimal 
response and minimize side effects (Bau-
mann et al., 2004). 
Intramuscular OLZ is a fast-acting for-
mulation that is also indicated for use in pa-
EXCLI Journal 2014;13:1163-1191 – ISSN 1611-2156 
Received: June 20, 2014, accepted: July 27, 2014, published: October 13, 2014 
 
 
1174 
tients with agitation associated with schizo-
phrenia or bipolar mania. This OLZ formula-
tion is at least as effective as intramuscular 
haloperidol or lorazepam in treating patients 
with acute agitation associated with schizo-
phrenia or bipolar mania, and has a faster 
onset of action (Wright et al., 2003; Lind-
borg et al., 2003). At doses of between 2.5 
and 10.0 mg per injection, the response is 
dose related. The drug has a favourable safe-
ty profile (Breier et al., 2002). 
It is now available also OLZ long-acting 
formulation. OLZ long-acting injection 
(OLAI) is a crystalline salt composed of 
olanzapine and pamoic acid, that is suspend-
ed in an aqueous solution which permits a 
depot intramuscular formulation of olanzap-
ine. Once injected in the gluteal muscle, the 
two components of the salt slowly dissociate 
into separate molecular compounds, olanzap-
ine and pamoic acid. The rate of dissolution 
of the salt is slow, allowing for a gradual re-
lease of olanzapine into the circulation over 
2 to 4 weeks. 
The half-life of olanzapine pamoate is 30 
days, and its steady state is reached approx-
imately at 12 weeks. Oral supplementation 
of olanzapine should not be required during 
OLAI initiation, although a study indicates 
that ≥60 % of D2 receptor occupancy was 
reached only by the fifth injection cycle 
(Lindenmayer, 2010; Di Lorenzo and Brogli, 
2010). 
 
Quetiapine 
Quetiapine (QTP) is a dibenzothiazepine 
derivate approved for the management of 
acute and chronic psychotic disorders, the 
acute phase of mania and bipolar depression. 
QTP has been shown to be at least as effica-
cious as the typical antipsychotics chlor-
promazine and haloperidol in the short-term 
treatment of schizophrenia (Arvanitis et al., 
1997; Peuskens and Link, 1997). Controlled 
clinical trials have shown that it is well toler-
ated, not associated with a sustained increase 
in plasma prolactin concentrations, and has a 
low propensity to cause extrapyramidal 
symptoms (Small et al., 1997). 
QTP and the active human plasma me-
tabolite, norquetiapine (N-desalkylquetia-
pine) (N-QTP), interact with a broad range 
of neurotransmitter receptors. QTP and N-
QTP exhibit affinity for brain serotonin 
(5HT2) and dopamine D2 receptors. QTP has 
a lower affinity for D1 receptors. This com-
bination of receptor antagonism with a high-
er selectivity for 5HT2 relative to D2 recep-
tors seems to contribute to the clinical anti-
psychotic properties and low extrapyramidal 
undesirable effect (EPS) liability of QTP 
compared to typical antipsychotics. Addi-
tionally, N-QTP has high affinity for the 
norepinephrine transporter (NET). QTP and 
N-QTP also have high affinity at histaminer-
gic and adrenergic α1 receptors, with a lower 
affinity at adrenergic α2 and serotonin 
5HT1A, 5HT2A and 5HT2C receptors. QTP 
has no appreciable affinity at muscarinic or 
benzodiazepine receptors (Small et al., 
2002). 
On the other hand the dissociation time-
course of QTP at dopamine D2 receptors and 
at serotonin (5-HT) receptors should be con-
sidered: QTP such as other atypicals, CLZ, 
OLZ, ziprasidone and amisulpride all bind 
more loosely than dopamine to the dopamine 
D2 receptors and have dissociation constants 
higher than that for dopamine. These tight 
and loose binding data agree with the rates of 
antipsychotic dissociation from the human-
cloned D2 receptor. For instance, radioactive 
haloperidol and chlorpromazine, all dissoci-
ate very slowly over a 30-minute time span, 
while radioactive QTP, CLZ and amisulpride 
dissociate rapidly, in less than 60 seconds. 
These data also match clinical brain-imaging 
findings that show haloperidol remaining 
constantly bound to D2 in humans undergo-
ing 2 positron emission tomography (PET) 
scans 24 hours apart. Conversely, the occu-
pation of D2 by QTP or CLZ has mostly dis-
appeared after 24 hours (Seeman, 2002). 
At doses within the recommended thera-
peutic range, QTP instant release (IR) has a 
linear pharmacokinetic profile. QTP is rapid-
ly absorbed following the oral administration 
of all dose levels, with a median time to Tmax 
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of 1-1.5 hours. Its coadministration with 
food only marginally increases Cmax and 
AUC values (DeVane and Nemeroff 2001). 
There are no absolute bioavailability data 
because of the lack of an injectable formula-
tion, but preliminary data indicate that about 
70 % is absorbed. Apparent oral clearance 
ranges from 55 to 87 l/h, and Cmax values of 
53-117 µg/L were observed after the single 
administration of a 25 mg dose. Multiple 
dose studies show Cmax values of 778-
1080 ng/ml at doses of 250 mg/day. The ap-
parent oral volume of distribution ranges 
from 513 to 710 L. The drug is approximate-
ly 83 % bound to plasma proteins, and is 
eliminated with a mean half-life of approxi-
mately six hours. The primary route of elim-
ination is hepatic metabolism (DeVane and 
Nemeroff, 2001). 
QTP is extensively metabolized (at least 
20 metabolites have been identified): only 
two, 7-hydroxy-quetiapine and 7-hydroxy-N-
desalkyl-quetiapine (N-QTP) are pharmaco-
logically active (Grimm et al., 1997). In par-
ticular, N-QTP, a potent norepinephrine 
reuptake inhibitor and partial serotonin 5-
HT1A receptor agonist, has been suggested as 
a putative mediator of QTP antidepressant 
activity (Altamura et al., 2012). 
After single subclinical doses, the mean 
plasma clearance of QTP is reduced by only 
25 % in patients with severe renal impair-
ment (creatinine clearance 10-30 ml/min/ 
1.73 m2) or hepatic impairment (stable alco-
holic cirrhosis) (Gunasekara and Spencer, 
1998). The oral clearance of QTP seems to 
be lower (30-50 %) in elderly patients (63-85 
years) receiving 300-750 mg/day than in 
younger patients on similar regimens 
(Grimm et al., 2006). It shoud be noted that 
an age of >70 years has been found to be as-
sociated with a marked decline in the hepatic 
content of CYP3A4. Dose titration may 
therefore need to be slower in the elderly, 
and the daily dose lower than in younger pa-
tients. QTP does not generally show any 
clinically relevant gender-related pharmaco-
kinetic changes (DeVane and Nemeroff 
2001; Grimm et al., 2006) but Mauri et al. 
(2004b) found higher levels/doses per kg in 
women than men. 
The coadministration of drugs that are 
known to induce CYP3A4 (e.g. phenytoin, 
carbamazepine) may lead to a clinically rele-
vant decrease in QTP levels (Grimm et al., 
2006). 
Only a few studies have investigated the 
relationship between plasma QTP levels and 
clinical responses, all of which are short-
term and none have used a treatment period 
of more than six weeks. Although some data 
argue in favour of the existence of a relation-
ship between plasma QTP levels and clinical 
responses, they only provide some prelimi-
nary information about the meaning of plas-
ma QTP levels (Gefvert et al., 1998; Mauri 
et al., 2004b; Mauri et al., 2007b). Other au-
thors have failed to identify an optimal ther-
apeutic range for QTP (Fabre et al., 1995; 
Small et al., 1997). 
A suggested therapeutic range of 70-
170 ng/ml has been proposed by AGNP 
guidelines. TDM is therefore recommended 
as “useful” in order to check whether plasma 
concentrations are plausible for a given dose 
and optimize the clinical response in non re-
sponder patients with low concentrations 
(Baumann et al., 2004). 
Given the few data concerning the rela-
tionship between clinical responses and 
plasma QTP levels, some clues can be ex-
trapolated from PET studies of receptor 
blockades. A number of studies have inves-
tigated the relationship between the time-
course of CNS dopamine and serotonin re-
ceptor blockade and plasma drug concentra-
tions after the discontinuation of QTP treat-
ment, and shown that the disappearance of 
QTP from plasma is much more rapid than 
the decrease in serotonin receptor occupancy 
(Gefvert et al., 1998; Kapur et al., 2000; Ge-
fvert et al., 2001). A better, but not perfect, 
correspondence was observed between D2 
receptor dissociation and plasma QTP half-
life. These data indicate a discrepancy be-
tween the time-course of receptor occupancy 
and plasma QTP concentrations (Gefvert et 
al., 2001). 
EXCLI Journal 2014;13:1163-1191 – ISSN 1611-2156 
Received: June 20, 2014, accepted: July 27, 2014, published: October 13, 2014 
 
 
1176 
Kapur et al. (2000) found a clear curvi-
linear relationship between 5-HT2A receptor 
occupancy and plasma QTP levels, but only 
a weak relationship between plasma QTP 
levels and D2 receptor occupancy. In an albe-
it very small patient sample (n=5), Gevfert et 
al. (2001) found an apparently clear correla-
tion between plasma QTP levels and D2 re-
ceptor occupancy in a study that used 
PANSS, CGI and SAS to assess clinical out-
comes. The results showed that the data at 
QTP doses of <300 mg/day and >450 mg/ 
day were collected from individuals who dif-
fered clinically in that the former were un-
controlled and the latter were controlled on 
QTP treatment. These results suggest that a 
certain threshold plasma level and definite 
D2 occupancy is required for the efficacy of 
the treatment. 
It is also available QTP extended release 
(XR) formulation: once-daily dosing of the 
XR formulation showed peak and trough 
plasma levels and central D2 receptor occu-
pancy comparable to twice-daily dosing of 
the IR formulation (Mamo et al., 2008). 
More recently XR exhibited a less pro-
nounced D2 receptor occupancy peak recep-
tor occupancy levels remaining higher for 
longer compared with IR formulation (Bui et 
al., 2013). 
Once-daily quetiapine XR produced a 
similar area under the plasma concentration-
time curve (AUC), minimum plasma concen-
tration (Cmin) and a slightly lower maximum 
plasma concentration (Cmax) than the equiva-
lent dose of IR formulation given twice dai-
ly. In a crossover, head-to-head study, total 
daily exposure, measured by AUC at steady 
state, was less variable with XR versus IR 
(percent coefficient of variation 39.2 % ver-
sus 51.2 %, respectively). Compared with 
fasting, a high-fat meal increased the AUC 
and Cmax for XR formulation, whereas a light 
meal had no significant effect on these pa-
rameters (Bui et al., 2013).  
 
Amisulpride 
Amisulpride (AMI) might be considered 
from a clinical point of view a second-
generation antipsychotic which has been ap-
proved for the treatment of schizophrenia. It 
seems to be as effective as haloperidol in 
controlling the positive symptoms of schizo-
phrenia, and more effective than haloperidol 
in controlling negative and depressive symp-
toms (Carriere et al., 2000). 
AMI is a substituted benzamide deriva-
tive, and highly selective dopamine D2 and 
D3 receptor antagonist. In ex vivo binding 
studies, it is twice as selective for D3 recep-
tors as D2 receptors. It has no affinity for the 
D1, D4 and D5 receptor subtypes, and little 
affinity for adrenergic, histaminergic, sero-
tonergic or cholinergic receptors (Perrault et 
al., 1997). It has also demonstrated preferen-
tial affinity for presynaptic D2 and D3 recep-
tors at low doses (<10 mg/kg), leading to 
enhanced dopamine transmission, whereas 
higher doses antagonise postsynaptic D2 and 
D3 receptors, thus reducing dopamine trans-
mission. 
On the other hand atypicality of AMI, 
such as other atypical antipsychotics, could 
be attributed by transiently occupying D2 
receptors and then rapidly dissociating to 
allow normal dopamine neurotransmission. 
This could help also AMI to keep prolactin 
levels generally normal, to spare cognition 
and to obviate EPS (Seeman, 2002). 
Finally, it shows preferential affinity for 
limbic rather than nigro-striatal regions (Per-
rault et al., 1997).  
AMI is rapidly absorbed after oral ad-
ministration, and has an absolute bioavaila-
bility of 50 %. Cmax is 42-56 μg/L, and is 
reached in 1-4 hours (Tmax); steady-state is 
reached after 2-3 days. Its distribution vol-
ume is 5.8 L/kg and plasma protein binding 
is about 17 %. Its plasma elimination half-
life is 12 hours, with renal clearance of 17-
20 L/h. Excretion occurs mainly via the kid-
neys, with 22-25 % of an oral dose being re-
covered in the urine as unchanged drug. In 
patients with renal impairment, the drug‘s 
half-life is unchanged but systemic clearance 
is reduced by one-third and so dose adjust-
ments are required (Rosenzweig et al., 
2002).  
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AMI undergoes minimal metabolism in 
the liver, and produces only two main me-
tabolites, both of which are inactive. It is 
mainly eliminated renally and, interestingly 
enough, its rate of renal excretion is about 
2.5 times higher than that which might be 
expected from mere glomerular filtration. It 
is therefore likely that active drug secretion 
occurs. 
AMI is unlikely to interact with other 
drugs, and does not affect the activity of the 
cytochrome P450 system (Rosenzweig et al., 
2002). 
Age and gender have a significant effect 
on dose-corrected AMI plasma concentra-
tions, which are higher in older patients and 
women (Bergemann et al., 2004), possibly 
because of a gender difference in the drug’s 
renal clearance. Co-medication with lithium 
and clozapine increases dose-corrected AMI 
plasma concentrations (Mauri et al., 1996; 
Bergemann et al., 2004). 
Little is known about the therapeutic sig-
nificance of plasma AMI concentrations. On-
ly one study has considered the range of 
therapeutic plasma AMI levels, and the cor-
relation beween daily oral doses and plasma 
concentrations (Bergemann et al., 2004). 
There was a positive correlation (r = 0.50, 
p <0.001) between the daily AMI dose and 
plasma concentrations. As in the case of 
most antipsychotics, patients commonly 
show great interindividual variance in plas-
ma AMI levels. The therapeutic plasma AMI 
levels of about 367 ng/ml were associated 
with stable clinical improvement. The thera-
peutic range of 100-400 ng/ml has been pro-
posed by the AGNP-TDM consensus guide-
lines, which is based on data from non-
systematic clinical experiences (Baumann et 
al., 2004). 
 
Ziprasidone 
Ziprasidone (ZPS) is a benzothiazolylpi-
perazine developed from the chemically-
related antipsychotic tiospirone, and has 
been reported to be effective on positive, 
negative and depressive symptoms in the 
short-term treatment of schizophrenia (Caley 
and Cooper, 2002). It has been associated 
with a low incidence of sedative effects, little 
likelihood of extrapyramidal symptoms and 
postural hypotension, no anticholinergic ef-
fects, and only mild transient hyperprolacti-
naemia (Gunasekara et al., 2002). Unlike 
most atypical antipsychotic drugs, ZPS is not 
associated with weight gain, hyperlipidemia 
or high plasma glucose levels (Caley and 
Cooper, 2002). 
This clinical profile may be related to its 
unique combination of pharmacological ac-
tivities at human receptors: it is a dopamine 
D2 and serotonin 5-HT2A receptor antagonist 
(with greater in vitro affinity for the 5-HT2A 
receptor) (Schmidt et al., 2001; Caley and 
Cooper, 2002), a 5-HT1A agonist, and a 5-
HT2C and 5-HT1B/D antagonist. Like antide-
pressant drugs, it also inhibits the reuptake of 
serotonin and noradrenaline (Schmidt et al., 
2001; Gunasekara et al., 2002). 
A significant positive correlation be-
tween plasma ZPS levels and the occupancy 
of both D2 and 5-HT2 receptors has been re-
ported, with the relationship described by a 
hyperbolic curve (Mamo et al., 2004). 
From a pharmacokinetic point of view 
the absolute bioavailability of a 20 mg oral 
dose of ZPS under fed conditions is 60 %. 
The duration and extent of ZPS absorption 
may be as much as doubled in the presence 
of food, whereas its half-life is shorter than 
under fasting conditions. ZPS has a mean 
apparent distribution volume of 1.5 L/kg. It 
is highly bound to plasma proteins, primarily 
albumin and alpha-1-acid glycoprotein. It’s 
pharmacokinetics seem to be linear as both 
AUC and Cmax linearly increase with increas-
ing doses, and its half-life of ZPS at steady-
state has been reported to be 8-10 hours 
(Miceli et al., 2000; Wilner et al., 2000). Age 
and gender do not have a clinically signifi-
cant influence on the pharmacokinetics of 
ZPS (Stimmel et al., 2002). 
ZPS is highly metabolized in humans, 
with less than 5 % of the administrated dose 
being excreted in unchanged form. The ini-
tial metabolic pathway involves CYP3A4, 
which is responsible for two alternative oxi-
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dation pathways: oxidation at the sulphur 
atom of the benzisothiazole ring to yield ZPS 
sulfoxide, and oxidative cleavage to yield 
benzisothiazole piperazine (BITP) (Beedham 
et al., 2003). These metabolites themselves 
undergo varying degrees of subsequent me-
tabolism. CYP3A4 is also thought to be the 
enzyme responsible for the formation of ZPS 
sulfone, the only metabolite that may con-
tribute to the clinical activity of ZPS. There 
are 12 different circulating metabolites of 
ZPS, four of which are major: BITP-
sulfoxide, BITP-sulfone, ZPS-sulfoxide and 
S-methyldihydro ZPS (Prakash et al., 1997).  
Clinical studies have shown mean plasma 
concentrations of 35-109 ng/ml at the doses 
commonly used in clinical settings (80-
160 mg/day), with steady-state being reached 
by the seventh day (Daniel et al., 1999; Mau-
ri et al., 2007c). There are no published stud-
ies of the relationships between plasma ZPS 
levels and clinical responses, and so the op-
timal therapeutic range is still poorly de-
fined. According to the AGNP consensus 
guidelines, TDM is “probably useful” in pa-
tients receiving ZPS because of the current 
lack of valid clinical data. It may be useful to 
check whether plasma concentrations are 
plausible for a given dose (Baumann et al., 
2004). 
It is available the ZPS mesylate intra-
muscular formulation. Its pharmacokinetics 
include the rapid attainment of therapeutic 
drug levels (Tmax <60 minutes post-dosing), a 
mean terminal elimination half-life of 2-5 
hours, approximately 100 % bioavailability, 
drug exposure that increases in a dose-
related manner, and little drug accumulation 
even after three days of repeated intramuscu-
lar administrations, with low concentrations 
of ZPS 12-18 hours after the last intramuscu-
lar injection (Preskorn, 2005). The rapid 
plasma clearance of ZPS after intramuscular 
administration leads to little or no persis-
tence of plasma drug levels when switching 
from intramuscular to oral drug administra-
tion. No clinically significant age, sex or 
race related effects on the pharmacokinetics 
of intramuscular ZPS have been reported 
(Miceli et al., 2005). 
 
Aripiprazole 
Aripiprazole (ARI) might be considered 
a “third-generation” antipsychotic agent. 
ARI has been reported to be effective and 
well tolerated in short-term and longer-term 
studies in patients with schizophrenia or 
schizoaffective disorders (Swainston and 
Perry, 2004; Stip and Tourjman, 2010). In 
addition, a potential role for ARI in acute 
mania so as in depression is supported by the 
findings of clinical trials in patients with bi-
polar I or major depressive disorder (Weber 
et al., 2008; De Fazio et al., 2010; Brown et 
al., 2013; Stewart et al., 2014). 
The most frequent reported adverse ef-
fects are headache, anxiety, insomnia, nau-
sea, vomiting, and lightheadedness. The in-
cidence of extrapyramidal symptoms is low-
er than with haloperidol. The increase in pro-
lactin levels and QTc prolongation are re-
ported to be similar in patients treated with 
ARI and placebo. 
ARI is a quinolinone derivative. It shows 
a high affinity for dopamine D2 and D3 re-
ceptors, and serotonin 5-HT1A, 5-HT2A and 
5-HT2B receptors. In particular ARI has par-
tial-agonist activity at dopamine D2 and D3 
receptors and serotonin 5-HT1A receptors, 
and antagonist activity at 5-HT2A receptors 
(Lawler et al., 1999; Jordan et al., 2002; Bur-
ris et al., 2002). 
Really the mechanism of action of ARI is 
not yet known, but evidence suggests that its 
efficacy in the treatment of the positive and 
negative symptoms of schizophrenia and its 
lower propensity for extrapyramidal symp-
toms (EPS) may be attributable to ARI par-
tial agonist activity at dopamine D2 recep-
tors. At serotonin 5-HT1A receptors, in vitro 
studies have shown that aripiprazole acts as a 
partial agonist whereas at serotonin 5-HT2A 
receptors aripiprazole is an antagonist. The 
main active metabolite, dehydro-aripipra-
zole, has affinity for dopamine D2 receptors 
and thus has some pharmacological activity 
similar to that of the parent compound. 
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A positron emission tomography study in 
patients with schizophrenia found that at 
10 mg/day ARI had high mean occupancy at 
striatal D2 receptors (putamen, 87 %; cau-
date, 93 %; ventral striatum, 91 %), lower 
mean occupancy at 5-HT2 receptors (54 %–
60 %), and lower mean occupancy at 5-HT1A 
receptors (16 %). A study that analyzed the 
relationship between occupancy at the D2 
receptor and clinical response in schizophre-
nia suggested that at least 60 % of receptors 
must be blocked for psychotic symptoms to 
be reduced (Mamo et al., 2007). 
As it has partial agonist activity on do-
pamine D2 and serotonin 5-HT1A receptors, 
and also antagonizes 5-HT2A receptors, is 
considered a "dopamine-serotonin stabilizer" 
(Yokoi et al., 2002; McGavin and Goa, 
2002). 
From a pharmacokinetic point of view 
ARI is well absorbed, with peak plasma con-
centrations occurring within 3-5 hours of 
administration. Oral availability is 87 %. The 
mean elimination half-life is about 75 hours 
for ARI and 94 hours for its active metabo-
lite. A linear pharmacokinetic profile has 
been observed at all doses between 5 and 
30 mg/day, with peak plasma concentrations 
being reached within 3-5 hours and steady-
state plasma concentrations being reached by 
day 14. The elimination half-life is 48-68 
hours, distribution volume 404 L (4.9 L/kg), 
and oral clearance 3.3-4.0 L/h. Protein bind-
ing is extensive (>99 %), primarily to albu-
min (Winans, 2003). 
It has been found that therapeutic doses 
of lithium and divalproex have no clinically 
significant effects on the pharmacokinetics 
of ARI in patients with schizophrenia or 
schizoaffective disorder (Citrome et al., 
2005; DeLeon et al., 2004). 
Metabolism takes place in the liver via 
CYP3A4 and CYP2D6, primarily as a result 
of dehydrogenation, hydroxylation and N-
dealkylation. At steady-state, about 40 % of 
the plasma ARI level is represented by the 
major metabolite, dehydroARI. Although it 
is known that the affinity of dehydroARI to 
D2 receptors is similar to that of ARI, its 
contribution to ARI’s clinical effects has not 
been assessed. Excretion occurs via the kid-
ney and liver, with 25 % of the dose being 
recovered in the urine (<1 % unchanged) and 
55 % in the feces (18 % unchanged) (Cit-
rome et al., 2005; Mallikaarjun et al., 2004). 
According to the manufacturer, no dose ad-
justments are required on the grounds of he-
patic or renal impairment, age, gender, race 
or smoking status. 
The dosage adjustment of ARI is neces-
sary when it is coadministered with CYP3A4 
and CYP2D6 inhibitors (since aripiprazole 
concentration is increased) and with inducers 
of CYP3A4 (since aripiprazole concentration 
is decreased) (Mallikaarjun et al., 2004). 
There are no published data concerning 
plasma ARI levels, and so it is not known if 
a therapeutic plasma concentration range 
even exists: studies of the relationships be-
twen plasma levels and clinical responses are 
required. 
There are two ARI formulations for in-
tramuscular use with different dosages, dos-
ing frequencies, and indications.  
ARI injection (9.75 mg per vial) is a 
short-acting formulation indicated for agita-
tion in patients with schizophrenia or mania. 
ARI Depot is a long-acting ARI formula-
tion, available in several countries in Europe 
and USA, with 4 week dosing intervals indi-
cated for the treatment of schizophrenia. 
ARI long-acting activity is presumably 
primarily due to the parent drug, aripipra-
zole, and to a lesser extent, to its major me-
tabolite, dehydro-aripiprazole, which has 
been shown to have affinities for D2 recep-
tors similar to the parent drug and represents 
about 29 % of the parent drug exposure in 
plasma. 
ARI absorption into the systemic circula-
tion is slow and prolonged following intra-
muscular injection due to low solubility of 
ARI particles. Following a single intramus-
cular dose, the plasma concentrations of ARI 
gradually rise to reach maximum plasma 
concentrations at a median Tmax of 5-7 days. 
The mean ARI terminal elimination half-life 
is 29.9 days and 46.5 days after every 4-
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week injection of ARI long-acting 300 mg 
and 400 mg, respectively, and steady state 
concentrations are attained by the fourth 
dose. Approximate dose-proportional in-
creases in ARI and dehydro-aripiprazole 
concentrations and AUC parameters are ob-
served after every four week ARI long-
acting injections of 300 mg and 400 mg. 
Elimination of aripiprazole is mainly 
through hepatic metabolism involving two 
P450 isozymes, CYP2D6 and CYP3A4. Ari-
piprazole is not a substrate of CYP1A1, 
CYP1A2, CYP2A6, CYP2B6,CYP2C8, 
CYP2C9, CYP2C19, or CYP2E1 enzymes. 
 
Asenapine 
Asenapine (ASN), available as an orally 
disintegrating tablet administered sublingual-
ly, differs from other oral antipsychotics in 
that it is absorbed through the oral mucosa. 
ASN has recently been added as a treat-
ment option for schizophrenia for adults by 
the US Food and Drug Administration and as 
monotherapy or adjunctive therapy with lith-
ium or valproate in the treatment of manic or 
mixed episodes associated with bipolar I dis-
order. ASN is also indicated in the European 
Union for the treatment of moderate to se-
vere manic episodes associated with bipolar I 
disorder (Szegedi et al., 2012; Bobo, 2013). 
A sedative profile of the drug is generally 
proved. 
The human receptor signature of ASN is 
characterized by high affinity for serotonin 
(5-HT1A, 5-HT1B, 5-HT2A, 5-HT2B, 5-HT2C, 
5-HT5, 5-HT6, 5-HT7), α-adrenergic (α1, α2A, 
α2B, α2C), dopamine (D1, D2, D3, D4) and his-
tamine (H1, H2) receptors, but minimal affin-
ity for muscarinic receptors (Peeters et al., 
2011). 
In particular, ASN has substantially 
higher affinity (Ki in nM) to serotonin 5-
HT2C (0.03), 5-HT2A (0.06), 5-HT7 (0.13), 5-
HT2B (0.16), 5-HT6 (0.25), and dopamine D3 
(0.42) receptors than to dopamine D2 recep-
tors (1.3). Binding affinity to histamine H1 
(1.0), dopamine D4 (1.1), norepinephrine α1 
(1.2), and norepinephrine α2 (1.2) receptors 
approximates that for dopamine D2 recep-
tors. Low affinity to muscarinic receptors 
would theoretically predict a low propensity 
for causing anticholinergic side effects. The 
remaining complex pharmacodynamic pro-
file of ASN is of potential interest, particu-
larly for the serotonin 5-HT7 receptor where 
there are pre-clinical findings of a possible 
pro-cognitive effect (Ballaz et al., 2007). An-
tagonism at serotonin 5-HT2C receptors can 
also theoretically be expected to produce de-
sirable clinical effects, including improve-
ments in both cognition and mood (Shayegan 
and Stahl, 2004; Citrome, 2013a). 
In vitro studies have demonstrated that 
ASN is metabolized to N-desmethylasena-
pine, asenapine N-oxide, 11-hydroxyasena-
pine. The main metabolite, N-desmethyl-
asenapine, and the phase II metabolite, 
asenapine N+-glucuronide, show affinities 
that are 10- to 100-fold lower than that of 
asenapine for the most relevant of these re-
ceptors; an exception is 5-HT1A, for which 
the affinity of N-desmethylasenapine is simi-
lar to that of ASN (Peeters et al., 2011). 
The pharmacokinetic characteristics of 
ASN are reported in Table 3. It is rapidly 
absorbed. Absolute bioavailability is 35 %, 
mean Cmax is approximately 4 ng/mL, and 
Tmax is 0.5 to 1.5 h. Steady-state concent-
rations are reached within 3 days of twice-
daily dosing. Food or water may decrease 
asenapine exposure. It is rapidly distributed 
throughout the body. Vd is approximately 20 
to 25 L/kg; 95 % bound to plasma proteins. 
ASN is metabolized in the liver by direct 
glucuronidation by UGT1A4 and by oxida-
tive metabolism by CYP-450 isoenzymes 
(predominantly CYP1A2). Elimination is 
50 % in urine and 40 % in feces. The mean 
terminal half-life is approximately 24 h. 
Plasma Cl after IV administration is 52 L/h. 
Pharmacokinetics are similar in patients with 
varying degrees of renal impairment com-
pared with healthy patients. The effect of 
dialysis on the pharmacokinetics of asenap-
ine has not been studied. Severe hepatic im-
pairment exposure was 7 times higher than 
in healthy patients; mild or moderate hepatic 
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Table 3: Pharmacokinetic characteristics of new oral antipsychotics (modified by Citrome, 2013a) 
 Iloperidone Asenapine Lurasidone Cariprazine 
(CRP) 
Pharmacokinetics     
     
Time to peak  
PL 
2–4 h 0.5–1.5 h 1–3 h 3–4 h 
     
Elimination 
T1/2 
CYP2D6 exten-
sive metaboliz-
ers: 18 h (23-26 
for metabolites); 
CYP2D6 poor 
metabolizers: 
33 h (31-37 for 
metabolites) 
24 h 18 h  
(at 40 mg/day) 
2-5 days 
     
Protein-bound  95 %  95 % 99 % Pending 
     
Route of metabolism CYP2D6, 
CYP3A4 
UGT1A4, 
CPY1A2 
CYP3A4 CYP3A4, 
CYP2D6 
     
Important metabolites P88 (in equili-
brium; crosses 
the BBB), P95 
(does not cross 
the BBB) 
Activity is pri-
marily due to 
the parent drug
Two active me-
tabolites with 
shorter t1/2 
than the parent 
compound 
Desmethyl-
CRP, 
didesmethyl-
CRP the latter’s 
t1/2 longer than 
that for CRP (-3 
weeks) 
PL, Plasma Levels; BBB, Blood Brain Barrier;  t1/2, half-life  
 
 
impairment exposure was 12 % higher than 
in healthy patients. In elderly patients ASN 
Cl is decreased, increasing exposure by 30 % 
to 40 % (Peeters et al., 2011; Citrome, 2014). 
 
Lurasidone 
Chemically, lurasidone (LRS) is structur-
ally related to perospirone and ziprasidone 
and other benzisothiazoles including the 
benzisoxazole derivatives risperidone, its 
active metabolite paliperidone, and iloperi-
done. LRS has shown efficacy in the treat-
ment of acute exacerbation of schizophrenia 
in a series of short-term placebo controlled 
studies and in a more recent longterm studies 
(Bobo, 2013; Stahl et al., 2013). 
LRS has high affinity for the dopamine 
D2 and 5-HT2A receptors. However, it has the 
highest affinity of any atypical antipsychotic 
for the 5-HT7 receptor and its potent 5-HT7 
receptor antagonism, might be beneficial for 
mood and cognition (Harvey et al., 2011; 
Luoni et al., 2014). 
LRS also has high affinity for the 5-HT1A 
subtype, with which it interacts as a partial 
agonist such as the benzisothiazoles perospi-
rone and ziprasidone, but not risperidone and 
iloperidone (Harvey et al., 2011). 5-HT1A 
receptors, widely expressed in the central 
nervous system and upregulated in the 
frontal cortex, have been implicated in the 
enhancement of cognitive function in the 
schizophrenic patients. The stimulation of 
these receptors could normalize frontal cor-
tex function and reduce side effects induced 
by dopamine D2 receptor blockade such as 
EPS, including dystonia and diskinesia, and 
the iperprolactinemia (Citrome, 2012b). 
In addition to the other unique binding 
profiles of other monoamine receptors, the 
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lack of affinity for the dopamine D4 receptor 
by LRS might also contribute, at least partly, 
to its cognitive enhancing effect (Murai et 
al., 2014). 
LRS has affinity for α2C-adrenergic re-
ceptors and low affinity for α1-adrenergic 
receptors (orthostatic hypotension) (Citrome, 
2013b). 
It has minimal affinity for 5-HT2C recep-
tors and it has negligible affinity for hista-
mine H1 and muscarinic receptors, which are 
linked to sedation and weight gain, and have 
negative cognitive effects. 
From a pharmacokinetic point of view 
LRS is rapidly absorbed, reaching peak con-
centrations within 1.5–3 hours (Tmax) after 
single and multiple oral doses. Its pharmaco-
kinetics was linear in the range of 20 to 
160 mg in healthy and schizophrenic sub-
jects, but interindividual variability was high 
(30 %–60 %) in terms of plasma maximum 
concentrations (Cmax) and area under the 
curve (AUC). Absorption increased when the 
drug was taken with food AUC and Cmax in-
creasing two- to three-fold. LRS has high 
binding to human plasma albumin and alpha-
1-glycoprotein (99 %). 
Elimination is essentially by metabolism, 
primarily involving CYP3A4. The two main 
metabolites, the acidic derivative ID-20219 
and its hydroxylated derivative ID-20220, 
have negligible affinity for the D2 receptors 
and 5-HT1A, 5-HT2A, and 5-HT7 receptors.  
The mean terminal half-life at steady 
state in patients with schizophrenia ranges 
28.8 and 37.4 hours. Thus, after repeated 
oral doses in schizophrenic patients, steady-
state concentrations of lurasidone were 
achieved within 7 days (Caccia et al., 2012; 
Citrome, 2013b) (Table 3). 
 
Iloperidone 
Iloperidone (ILP) was recently approved 
by the US Food and Drug Administration for 
the acute treatment of schizophrenia (Arif 
and Mitchell, 2011; Rado and Janicak, 
2014). 
ILP shows high affinity for dopamine D3 
receptors, 5HT2A receptors, norepinephrine 
α1 receptors and an intermediate to high af-
finity for norepinephrine α2C receptors. It 
shows an intermediate affinity for dopamine 
D2A and D4 receptors, 5HT1A, 5HT2C, and 
5HT6 receptors. Moreover ILP shows low 
affinity for norepinephrine α2A, α2B, ß1, ß2, 
receptors, histamine H1 receptors, dopamine 
D1 and D5 receptors. Negligible affinity is 
for muscarinic μ1–μ5 receptors, dopamine 
and norepinephrine reuptake transporters 
(Rado and Janicak, 2014). 
Of clinical importance is the relatively 
high affinity for noradrenergic α1 receptors 
(Ki 0.36 nM), compared with the affinity for 
serotonin 5-HT2A and dopamine D2 receptors 
(Ki 5.6 and 6.3 nM, respectively). This is the 
explanation for iloperidone’s potential for 
dizziness and orthostatic hypotension and 
this potent effect at noradrenergic α1 recep-
tors is the principal reason for the require-
ment that ILP be titrated to its therapeutic 
target dose range of 12–24 mg/day. 
The randomized controlled trials of ILP 
tested several doses of ILP vs placebo, and 
all employed twice daily (bid) dosing even 
though the elimination half-life approximates 
24 h, which would possibly justify once-
daily dosing once titration to a tolerable dose 
has taken place. An open-label extension 
study did suggest that 12 mg given once dai-
ly at bedtime was efficacious and tolerable 
(Cutler et al., 2013). 
Other receptor-binding characteristics 
may be important clinically. Low affinity to 
muscarinic receptors would theoretically 
predict a low propensity for causing anticho-
linergic side effects, including cognitive dys-
function and gastrointestinal disturbances, at 
clinically relevant doses (Citrome, 2013a). 
Low affinity to histamine H1 receptors would 
theoretically predict a low propensity for 
causing sedation or weight gain (Shayegan 
and Stahl, 2004). However, proof that these 
receptor binding affinities are clinically rele-
vant in the day-to-day treatment of patients 
requires the conduct of clinical trials to test 
these hypothesized effects. 
Pharmacokinetic studies have determined 
that iloperidone is well absorbed orally, with 
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a bioavailability of 96 %. Peak plasma con-
centration (Cmax) of ILP is reached 2–4 hours 
after oral administration. Its elimination half-
life ranges from 18 hours for extensive cyto-
chrome P450 2D6 (CYP2D6) metabolizers 
to 33 hours for poor metabolizers. It is me-
tabolized in the liver by the CYP3A4 and 
CYP2D6 enzyme pathways and circulates 
95 % bound to serum proteins. ILP has two 
major metabolites: P88-8991 and P95-
12113. P88-8991 shares similar receptor 
binding affinities with the parent compound. 
P95-12113 exhibits a lower affinity for the 
5HT2A receptor, does not cross the blood–
brain barrier, and therefore does not contrib-
ute to the clinical effects of ILP. P95-12113 
binds to receptors with a significantly lower 
affinity than ILP. The main pharmacokinetic 
characteristics of iloperidone are reported in 
Table 3 (Citrome, 2013a; Rado and Janicak, 
2014). 
 
Cariprazine 
Cariprazine is a potential antipsychotic 
awaiting approval from the US Food and 
Drug Administration. CRP is in late-stage 
clinical development for the treatment of 
schizophrenia, bipolar disorders and as an 
adjunctive agent for the treatment of major 
depressive disorder. Clinical trials showed 
that CRP should be titrated to target doses 
(3-9 mg/day) (Citrome, 2013b). 
Cariprazine (CRP) is a dopamine D2- and 
D3-receptor partial agonist, with higher affin-
ity for D3 receptors, as opposed to the D2 an-
tagonism of most older antipsychotic agents 
(Seneca et al., 2011; Caccia et al., 2013). In 
particular CRP is a dopamine D3-preferring 
D3/D2 receptor partial agonist presently con-
sidered for the treatment of schizophrenia 
and bipolar disorders (Citrome, 2013a-c). 
Binding affinities (Ki) for dopamine D3 re-
ceptors (0.085) are an order of magnitude 
higher than for D2 receptors (0.49–0.69). At 
present, ARI and CRP are the only dopamine 
D2 partial agonists commercially available 
for the treatment of psychiatric disorders 
(Citrome, 2013b). 
CRP is also a partial agonist at serotonin 
5-HT1A receptors with a Ki of 3. Differing 
from many other second generation antipsy-
chotics, the binding of CRP at serotonin 5- 
HT2A receptors is relatively weaker, with a 
Ki of 19. Theoretically, dopamine D3-
preferring agents may exert pro-cognitive 
effects, as evidenced in animal studies 
(Gyertyán et al., 2011). Serotonin 5-HT1A 
partial agonism, a property CRP also shares 
with ARI and LRS, is also thought to possi-
bly benefit negative symptoms and cognitive 
deficits (Blier and Ward, 2003; Ohno, 2011). 
CRP is rapidly absorbed, reaching peak 
concentrations between 3 and 4 hours after 
oral dosing in healthy subjects. Food mar-
ginally delayed the absorption of cariprazine, 
but did not affect the extent of its absorption 
after a single 2 mg oral dose. Its pharmaco-
kinetics were linear in terms of area under 
the concentration–time curve (AUC) but 
maximum concentrations were more than 
proportional within the dose range from 3 to 
5 mg in healthy subjects. Mean half-life was 
2–5 days (1.5–12.5 mg/day). Cariprazine is 
then primarily cleared by hepatic metabo-
lism, as are most lipophilic antipsychotics. 
There are two active metabolites of note: 
desmethyl-cariprazine and didesmethyl-
cariprazine. The half-life of didesmethyl- 
cariprazine is substantially longer than that 
of cariprazine, and systemic exposure to 
didesmethyl-cariprazine can be several times 
higher than that for CRP (Caccia et al., 
2013). The pharmacokinetic properties of 
CRP are reported in Table 3. 
 
GENERAL CONCLUSIONS 
The choice of the best antipsychotic 
treatment for an individual patient appears 
complex. It should be considered the phar-
macological anamnestic history of the pa-
tients including the previous history of ther-
apeutic response and tolerability with other 
medications so as individual patient prefer-
ences. Patients may also have specific sensi-
tivities to certain adverse effects of medica-
tion, such as akathisia, sedation, or weight 
gain. Having different options in order to 
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optimize efficacy and tolerability for the in-
dividual patient is desirable. 
Four new second-generation antipsychot-
ics are available iloperidone, asenapine, 
lurasidone and in the next future cariprazine. 
Similar to ziprasidone and aripiprazole, these 
new agents have a lower propensity for 
weight gain and metabolic abnormalities 
than older second-generation antipsychotics 
such as olanzapine or clozapine; lurasidone 
is reported be best in class in terms of mini-
mizing untoward alterations in body weight 
and metabolic variables. Asenapine generally 
have a more sedative profile. 
However, iloperidone, asenapine, lura-
sidone, (and cariprazine) differ among them-
selves in terms of on-label dosing frequency, 
once daily for lurasidone (and cariprazine), 
versus twice daily for iloperidone and 
asenapine, the need for initial titration to a 
therapeutic dose for iloperidone (and 
cariprazine), requirement to be taken sublin-
gually for asenapine, requirement for admin-
istration with food for lurasidone. They also 
differ for lengthening of the ECG QT inter-
val, greater for iloperidone than for asenap-
ine while no effect observed with lurasidone. 
Adverse effects like akathisia have been ob-
served with cariprazine, lurasidone and 
asenapine but not with iloperidone. Sedation 
was reported more frequenly with asenapine. 
Therapeutic drug monitoring is not strict-
ly necessary for all of the new antipsychotic 
drugs because there are no unequivocal data 
supporting a relationship between plasma 
drug levels and clinical outcomes or side ef-
fects, with the exception of the concentra-
tion-dependent pro-convulsant effects of 
CLZ. On the other hand, there are no clinical 
pharmacokinetic data, particularly long-term 
data concerning some of the other atypical 
antipsychotics, and this will require future 
research. It must be remembered that optimal 
plasma level ranges for CLZ, RSP and OLZ 
are proposed by some authors, but not all. 
Studies of QTP and AMI provide limited in-
formation, and there are no direct data for 
ZPS, ARI and the more recent second-gen-
eration antipsychotics. 
In any case, it is necessary to consider 
the value of acute pharmacokinetic data to 
characterize the new drug and the heuristic 
value of plasma level determination together 
with its medico-legal importance in the case 
of intoxication, etc. Moreover, the im-
portance of drug plasma level monitoring 
remains when it comes to identifying “pseu-
do-pharmacoresistance” problems such as 
poor compliance, high individual levels of 
metabolism, excessive water consumption by 
patients, excessive smoking, drug abuse, as 
well as the appearance of unpredictable side 
effects and possible drug interactions. 
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